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Background: Cytotoxic chemotherapy remains the main systemic therapy for gastro-oesophageal adenocarcinoma, but resistance to chemotherapy is
common, resulting in ineffective and often toxic treatment for patients. Predictive biomarkers for chemotherapy response would increase the probability of
successful therapy, but none are currently recommended for clinical use. We used global gene expression profiling of tumour biopsies to identify novel
predictive biomarkers for cytotoxic chemotherapy.
Methods: Tumour biopsies from patients (n¼ 14) with TNM stage IB–IV gastro-oesophageal adenocarcinomas receiving platinum-based combination
chemotherapy were used as a discovery cohort and profiled with Affymetrix ST1.0 Exon Genechips. An independent cohort of patients (n¼ 154) treated
with surgery with or without neoadjuvant platinum combination chemotherapy and gastric adenocarcinoma cell lines (n¼ 22) were used for qualification
of gene expression profiling results by immunohistochemistry. A cisplatin-resistant gastric cancer cell line, AGS Cis5, and the oesophageal
adenocarcinoma cell line, OE33, were used for in vitro validation investigations.
Results: We identified 520 genes with differential expression (Mann–Whitney U, Po0.020) between radiological responding and nonresponding
patients. Gene enrichment analysis (DAVID v6.7) was used on this list of 520 genes to identify pathways associated with response and identified the
adipocytokine signalling pathway, with higher leptin mRNA associated with lack of radiological response (P¼ 0.011). Similarly, in the independent cohort
(n¼ 154), higher leptin protein expression by immunohistochemistry in the tumour cells was associated with lack of histopathological response (P¼ 0.007).
Higher leptin protein expression by immunohistochemistry was also associated with improved survival in the absence of neoadjuvant chemotherapy, and
patients with low leptin protein-expressing tumours had improved survival when treated by neoadjuvant chemotherapy (P for interaction¼ 0.038). In the
gastric adenocarcinoma cell lines, higher leptin protein expression was associated with resistance to cisplatin (P¼ 0.008), but not to oxaliplatin (P¼ 0.988)
or 5fluorouracil (P¼ 0.636). The leptin receptor antagonist SHLA increased the sensitivity of AGS Cis5 and OE33 cell lines to cisplatin.
Conclusions: In gastro-oesophageal adenocarcinomas, tumour leptin expression is associated with chemoresistance but a better therapy-independent
prognosis. Tumour leptin expression determined by immunohistochemistry has potential utility as a predictive marker of resistance to cytotoxic
chemotherapy, and a prognostic marker independent of therapy in gastro-oesophageal adenocarcinoma. Leptin antagonists have been developed for
clinical use and leptin and its associated pathways may also provide much needed novel therapeutic targets for gastro-oesophageal adenocarcinoma.
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The incidence of adenocarcinomas of the oesophagus and gastro-
oesophageal junction has risen sharply in Western countries in
recent decades (Edgren et al, 2012). The majority present with late
stage, incurable disease or relapse after initial curative treatment.
The current 1-year and 5-year survival is 40–50% and 10–15%,
respectively (Kunz et al, 2012). The rising incidence and poor
clinical outcomes with current therapeutic approaches not only
indicate the urgent clinical need for new improved treatment
regimens, but also a need for the optimised use of currently
available therapeutic modalities to avoid the use of ineffective and
potentially toxic treatments.
The addition of trastuzumab to cisplatin and 5fluorouracil (5FU)
has been shown to be an effective palliative approach in patients
with advanced gastro-oesophageal adenocarcinoma that are HER2
positive (Bang et al, 2010). Progress with targeted therapies has
otherwise been limited (Ohtsu et al, 2011; Lordick et al, 2013;
Waddell et al, 2013). As only 10–15% of patients have HER2-
positive cancers, there is currently no targeted therapy option
available for the majority of patients in whom conventional
cytotoxic chemotherapy remains the only systemic option. Combi-
nation chemotherapy is effective in both early-stage and advanced-
stage disease. In early-stage disease, neoadjuvant chemotherapy with
cisplatin and 5FU, or perioperative chemotherapy (neoadjuvant and
adjuvant) with epirubicin, cisplatin and 5FU, has proven to be
effective (Cunningham et al, 2006). In advanced disease,
combination chemotherapy with cisplatin or oxaliplatin together
with 5FU or capectiabine has palliative benefits (Cunningham et al,
2008). The addition of epirubicin or docetaxel as triplet regimens
may provide small additional benefits (Cunningham et al, 2008;
Pozzo and Barone, 2008). However, only those patients who
respond to chemotherapy benefit from it. Although patients who
respond clinically, radiologically or histopathologically to neoad-
juvant chemotherapy have an improved survival, the survival for
those who do not respond is not significantly different to those
treated with surgery alone (Kelsen et al, 2007). Similarly, in
advanced disease, objective response rates to chemotherapy are 30–
60%, and there is a significant relationship between radiological
response and survival (Ichikawa and Sasaki, 2006). The delivery of
ineffective chemotherapy treatment in this palliative setting can be
catastrophic, as treatment-related toxicity has a significant negative
impact on the quality of life of patients and because disease
progression and associated deconditioning means that only a
minority of patients are suitable for second-line chemotherapy.
The importance of optimising the delivery of effective chemother-
apy and the avoidance of ineffective chemotherapy in patients with
both early- and advanced-stage gastro-oesophageal cancer is
accordingly emphasised.
To address these clinical concerns, a small number of recent
studies have utilised or advocated biomarker stratified treatment
selection in patients with gastro-oesophageal cancer (Ferry et al,
2007; Bang et al, 2010; Ohtsu et al, 2011; Petty, 2012). Molecular
biomarkers assayed in tumour pretreatment (usually diagnostic)
endoscopic biopsies have been demonstrated to be of value for
prediction of response to both cytotoxic and targeted therapies in a
number of human cancers including gastro-oesophageal adeno-
carcinomas (Bang et al, 2010; Sun et al, 2011). However, with the
exception of HER2 for trastuzumab, no other biomarker is
currently used in routine clinical practice in patients with gastro-
oesophageal adenocarcinoma, and specifically none for the
prediction of response to cytotoxic chemotherapy. The discovery
of predictive biomarkers that allow patient treatment stratification
for chemotherapy with sufficient sensitivity and specificity would
be very advantageous. These biomarkers could also provide new
therapeutic targets that might effectively be combined with
chemotherapy.
Because of the absence of qualified biomarkers for chemother-
apy response in gastro-oesophageal adenocarcinoma, we decided to
use gene expression profiling to discover novel predictive
biomarkers. Our experimental design involved the initial analysis
of gene expression profiling data derived from 14 patients in order
to identify genes that were differentially expressed in radiological
responders and nonresponders. Subsequently, we used gene
enrichment analysis to identify potential candidate predictive
biomarkers. Leptin, an adipocytokine, was one of the identified
candidate biomarkers and was selected for further validation as the
most biologically and clinically plausible predictive biomarker in
this cohort. The relationship between leptin expression, histo-
pathological response to chemotherapy and survival was
investigated in an independent set of gastro-oesophageal adeno-
carcinomas using a tissue microarray. Leptin expression was also
investigated in a panel of gastric adenocarcinoma cell lines to assess
the relationship between leptin expression and resistance to
cisplatin, oxaliplatin and 5FU, and the effect of a leptin receptor
antagonist on chemosensitivity in cell lines was investigated.
MATERIALS AND METHODS
Patients and treatment. The study was approved by the North of
Scotland Research Ethics Committee. Eligible patients had
histologically proven clinical TNM (7th edition) stage IB–IV
(staged with endoscopic ultrasound, CT scan chest, abdomen and
pelvis and FDG PET CT scan) distal oesophageal or gastro-
oesophageal junction adenocarcinomas, with measurable disease
on CT and were deemed suitable for treatment with either
preoperative/neoadjuvant or palliative chemotherapy following
multidisciplinary review at Aberdeen Royal Infirmary, Aberdeen,
UK. Neoadjuvant chemotherapy comprised treatment with three
cycles of epirubicin, cisplatin and capecitabine, and palliative
treatment comprised up to eight cycles of epirubicin, oxaliplatin
and capecitabine (regimen details provided in Supplementary
Information 1). Radiological response was assessed by computer
tomography (CT) of the chest and abdomen before therapy and
after three (neoadjuvant) or four (palliative) cycles of chemotherapy
according to RECIST criteria v1.1. Within the current study, stable
disease and progressive disease according to RECIST were
classified as radiological ‘nonresponders’ and partial and complete
response as ‘responders’.
Fourteen patients were recruited to the discovery set between
January 2009 and April 2010 (for patient details see Table 1). Of
the 14 patients, 10 were classified as responders and 4 as
nonresponders.
Gene expression profiling data were qualified in an independent
set of 154 gastro-oesophageal adenocarcinoma patients. Of these,
64 were treated with perioperative chemotherapy with 3 cycles of
epirubicin, cisplatin and capecitabine before surgery and 3 cycles
after surgery and 90 patients were treated by surgery alone at
Aberdeen Royal Infirmary, Aberdeen, UK, between 2004 and 2009
(TNM (6th edition) was used; for patient details see Table 2 and for
treatment details see Supplementary Information 1). Histopathology
of the resected specimens was reported by a specialist gastro-
intestinal pathologist (GIM) according to the Royal College of
Pathologists, London, data set. Tumour regression after neo-
adjuvant therapy was graded according to Mandard tumour
regression grade (TRG) and 3 out of 65 were TRG1, 5 out of 64
were TRG2, 12 out of 64 were TRG3, 24 out of 64 were TRG4 and
20 out of 64 were TRG5. TRG1–3 were classified as histopatho-
logical responders and TRG4–5 histopathological nonresponders
(Mandard et al, 1994). Tissue microarrays (TMAs) were
constructed as described previously with duplicate cores of tumour
taken for each case (Hope and Murray, 2011).
Biospecimens. A fresh specimen from the tumour was collected
endoscopically before starting chemotherapy (o5 days) and placed
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immediately into RNALater (Life Technologies, Carlsbad, CA,
USA), washed in ice-cold RNAase free water for 5min and ‘snap’
frozen in liquid nitrogen and stored at  80 C within 24 h.
Cell lines. AGS, KatoIII, NCI-N87 and Hs746T were obtained
from American Type Culture Collection (http://www.atcc.org/;
Manassas, VA, USA) and cultured as recommended by the
supplier. The OE33 was obtained from the European Collection of
Animal and Cell Culture (Centre for Applied Microbiology and
Research, Salisbury, UK, and cultured as recommended by the
supplier). The AZ521, Fu97, IM95, Ist1, MKN1, MKN45, MKN7,
MKN28, MKN45 and TMK1 cells were obtained from the Japanese
Collection of Research Bioresources/Japan Health Science Research
Resource Bank (http://cellbank.nibio.go.jp/) and cultured as
recommended. The SCH cells were a gift from Yoshiaki Ito
(Institute of Molecular and Cell Biology, Singapore) and grown in
RPMI media. The YCC1, YCC3, YCC6, YCC7, YCC10, YCC11
and YCC16 cells were a gift from Sun-Young Rha (Yonsei Cancer
Center, Seoul, South Korea) and were grown in minimum essential
medium supplemented with 10% fetal bovine serum, 100Uml 1
penicillin, 100Uml 1 streptomycin and 2mmol l 1 L-glutamine
(Invitrogen, Carlsbad, CA, USA). Cell lines were harvested and
fixed in 4% paraformaldehyde, cell pellets were prepared from
individual cell lines and further processed for paraffin embedding
as described previously (Waterworth et al, 2005). Generation of a
cisplatin-resistant gastric cancer cell line from AGS cells is
described in Supplementary Information 5.
In vitro cell proliferation assay. Adherent or semi-adherent cell
lines with doubling times o48 h were used in this analysis. Cells
were seeded in 100 ml of media in a 96-well plate and left to adhere
for 24 h, then 100 ml of drug diluted in media added at appropriate
concentrations and then incubated for 72 h at 37 1C and 5% CO2.
Complete media alone (no cells) served as a background control.
Blank and vehicle controls were included on each plate and then
cell proliferation assay performed. Cell proliferation assays were
performed using a tetrazolium compound-based colorimetric
method (MTS kit; Promega, Madison, WI, USA) according to
the manufacturer’s instructions and measured using an EnVision
2104 multilabel plate reader (Perkin Elmer, Turku, Finland) at
490 nm and a dose curve was fitted and IC50 values representing
the drug concentration required to elicit a 50% growth inhibition
calculated in Prism software (GraphPad PRISM v.5.02, La Jolla,
CA, USA). Inhibition of cell growth due to drug treatment was also
confirmed microscopically. Drugs used were cisplatin (479306-1G;
Sigma, St Louis, MO, USA), oxaliplatin (O9512; Sigma) and 5FU
(F6627-1G; Sigma). For each drug treatment, a minimum of three
independent replicate experiments with three intra-assay replicates
per data point were performed. The IC50 data for cisplatin,
oxaliplatin and 5FU for each cell line are provided in
Supplementary Information 6.
Leptin receptor antagonist experiments. The highly specific and
highly potent leptin receptor antagonist, superactive human leptin
antagonist (SHLA; Shpilman et al, 2011), was obtained from
Protein Laboratories Rehovot Ltd (PLR, Rehovot, Israel). The AGS
Cis5 or OE33 cells were seeded on to a 96-well plate in 100 ml
media and allowed to attach for 24 h, and then serum starved for
24 h. Subsequently, 100 ml of cisplatin diluted in media and/or
SHLA was added at the indicated concentrations, and cells were
incubated for 72 h at 37 1C and 5% CO2. Complete media alone
(no cells) served as a background control. Blank and vehicle
controls for cisplatin and SHLA when either was added alone were
included on each plate. Following the incubation period, MTT
assay (Sigma-Aldrich, Gillingham, UK) was performed according
to the manufacturer’s instructions and as described above. Results
presented are from experiments performed in triplicate, repeated 4
times.
Gene expression profiling. After histopathological confirmation,
gene expression was assessed in fresh tumour specimens using the
Affymetrix Exon 1.0 ST Array (1 084 639 exons and over 300 000
transcript clusters on each oligonucleotide microarray; www.affy-
metrix.com). Details of RNA extraction, sample preparation and
quality control are described in Supplementary Information 2.
Analysis of gene expression data. Gene expression data was
analysed using Genespring v.11.1 (Agilent, Wokingham, UK) and
DAVID v6.7 (NIH, Bethesda, MD, USA) (Huang et al, 2009) for
pathway analysis (described in Results and Supplementary
Information as indicated). Core probe sets on the Human Exon
1.0 ST array were processed using the RMA16 algorithm
Table 1. Details of the 14 patients in the Gene Expression profiling discovery cohort
Age Sex Site Stage
Radiological response
(R/NR) BMI
Chemotherapy
regimen
65 F Distal oesophagus IB NR (stable disease) 33.6 ECX
60 F GOJ type I IB NR (stable disease) 29.5 ECX
55 M GOJ type I IIIA R (partial response) 27.8 ECX
63 M GOJ type III IIIA NR (stable disease) 26.4 ECX
69 M GOJ type II IIIB R (partial response) 27.3 ECX
71 M GOJ type II IIIA R (partial response) 22 ECX
50 M GOJ type III IV R (partial response) 25.8 EOX
63 M Distal oesophagus IV R(partial response) 34.3 EOX
53 M Distal oesophagus IIIA NR (stable disease) 36.1 ECX
64 M GOJ type III IIIA R (partial response) 33.6 ECX
56 M GOJ type II IIIA R (partial response) 28.4 ECX
63 M Distal oesophagus IV R (partial response) 28.5 EOX
46 M GOJ type I IV R (partial response) 30.2 EOX
61 M Distal oesophagus IIIA R (partial response) 27.4 ECX
Abbreviations: BMI¼body mass index; ECX¼ epirubicin, cisplatin and capeciatbine; EOX¼ epirubicin, oxaliplatin and capecitabine; F¼ female; GOJ¼gastro-oesophageal junction; M¼male;
NR¼ nonresponder; R¼ responder. There was no significant relationship between stage (P¼ 0.899), BMI (P¼ 0.293) or regimen and response (P¼ 0.899).
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(Affymetrix, Santa Clara, CA, USA) that employs quantile
normalisation of log2 transformed data. Data were transformed
to median of all samples. Expression above background was
defined as all entities with signal intensitiesX20th percentile of all
intensity values in at least one sample. Gene expression data and
experimental details are available in MIAME compliant format
in ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) accession
number E-MEXP-3730.
Immunohistochemistry (IHC). Sections were cut from the tissue
microarrays and the cell line paraffin blocks. After dewaxing
according to a standard protocol, antigen retrieval was performed
by microwaving in 10mmol l 1 citrate (pH, 6.0) for 20min. Leptin
mouse monoclonal antibody (Y-20, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) was diluted 1 : 400 for TMA sections and
1 : 1200 for cell line sections. Immunohistochemistry was per-
formed using an autostainer (Dakocytomation, Glostrup,
Denmark) incubating the sections with the primary antibody for
1 h at room temperature and using the Envision (Dakocytomation)
detection system according to the manufacturer’s instructions and
as previously described (Duncan et al, 2008). Tissue and cell line
positive and negative controls without primary antibody were used.
All sections were double scored by two independent investigators
who were blinded to the clinical and chemosensitivity data. Leptin
expression was scored in tumour cells as negative, weak, moderate
or strong based on the intensity of cytosolic staining irrespective of
the number of positive cells. Overall, 92% agreement in scoring was
observed (k-statistic¼ 0.87). Scoring discrepancies were resolved
by examination of relevant sections jointly.
Statistical analyses. All other statistical analyses including survival
analysis were performed using PASW statistics v20 (IBM
Corporation, Armonk, NY, USA). Kaplan–Meier and Cox
proportional hazards analysis were used for survival analysis and
survival time was calculated in days from date of histological
diagnosis until date of death. Fisher’s exact test was used for the
assessment of categorical variables. All reported P-values are two
sided. A P-value of o0.05 was considered statistically significant.
RESULTS
Gene expression profiling identified the adipocytokine signalling
pathway as differentially expressed between chemotherapy
responders and nonresponders. We used a discovery set
(n¼ 14 patients, for clinicopathological data see Table 1) to
identify genes whose expression was significantly different between
radiological responders and nonresponders, resulting in a list of
520 genes (Mann–Whitney U, Po0.020, 520 genes listed in
Supplementary Information 3). In order to investigate potential
mechanisms of response and identify potential predictive bio-
markers and potential therapeutic targets for further qualification,
gene enrichment analysis (DAVID, v6.7 (Huang et al, 2009)) was
used to identify ‘over represented’ pathways in the list of 520 genes.
This analysis revealed six pathways as shown in Table 3 including
the adipocytokine pathway. Genes from this particular pathway
include leptin that was increased in nonresponding tumours
(Figure 1 and Table 4). Clinical and preclinical data support the
involvement of adipocytokine signalling in gastro-oesophageal
adenocarcinoma pathogenesis. Epidemiological studies demon-
strate a strong relationship between body mass index (BMI),
measures of visceral adiposity and risk of oesophageal and
gastro-oesophageal junctional adenocarcinoma and leptin receptor
is expressed in the majority of gastro-oesophageal adenocarcino-
mas (Abnet et al, 2008; Howard et al, 2010). Leptin has been shown
to stimulate proliferation and inhibit cell death in gastric and
oesophageal adenocarcinoma cells (Pai et al, 2005; Shida et al,
2005; Ogunwobi et al, 2006; Beales and Ogunwobi, 2007; Abnet
et al, 2008; Howard et al, 2010; Dong et al, 2013). Therefore the
involvement of the adipocytokine pathway in the response of
gastro-oesophageal adenocarcinomas to chemotherapy is plausible
biologically and clinically. For these reasons leptin was selected for
further investigation. We hypothesised that high leptin expression
in gastro-oesophageal adenocarcinomas is associated with resis-
tance and lack of response to chemotherapy.
Qualification of predictive and prognostic impact of leptin in an
independent clinical reference set. To provide further evidence to
support the potential utility of tumour leptin expression as a
predictive biomarker for chemotherapy response, the relationship
between leptin tumour protein expression in gastro-oesophageal
adenocarcinoma and response to treatment and survival was
investigated using IHC in an independent set of 154 resected
gastro-oesophageal adenocarcinomas, 64 of which received neoad-
juvant chemotherapy (for clinicopathological details see Table 2,
and treatment details see Supplementary Information 1).
Cytoplasmic leptin expression was seen in 92% of cases and, when
present, was invariably present in the majority of tumour cells,
with little observed variation in the proportion of tumour cells
staining positive for leptin. However, clear variation in the
Table 3. Pathway analysis using DAVID and the 520 gene set (Po0.02,
FC41.1) identified 6 significant pathways
Pathway Count EASE scorea
Adipocytokine signalling pathway 5 0.08
Pyruvate metabolism 4 0.07
Butanoate metabolism 4 0.05
Neuroactive ligand-receptor activation 12 0.05
Olfactory transduction 16 0.04
Valine, leucine and isoleucine metabolism 5 0.02
aExpression Analysis Systematic Explorer (EASE) score, a modified Fisher’s exact P-value.
Table 2. Details of 154 patients in the independent set tissue microarray
Variable Patients
Age (years)
Range 25–88
Mean 64
Gender
Male 109
Female 45
Site
Oesophagus (and Siewert type I and II) 69
Gastric (and Siewert type III) 85
Stage
I 34
II 55
III 56
IV 9a
aStage IV patients were all M1a (coealiac axis lymph node metastases only) and believed to
be resectable (R0) following multidisciplinary review.
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intensity of leptin IHC staining was observed, and classified as
strong, moderate or weak (Figure 2A). This scoring system was
therefore based upon the observed biological variability for leptin
IHC staining in gastro-oesophageal adenocarcinomas. Gastric and
junctional (Siewert type III) adenocarcinomas were more likely to
be strongly leptin positive (P¼ 0.0001, defined as strong vs weak/
moderate/negative), but otherwise there was no association
between leptin expression level and any of the clinicopathological
variables (gender, T stage, N stage, stage grouping; see
Supplementary Information 4). There was a highly significant
relationship between strong leptin expression and lack of
histopathological response to neoadjuvant chemotherapy
(P¼ 0.007, Figure 2B), consistent with the results from gene
expression profiling in the discovery set.
Strong leptin expression was also associated with better survival
in this cohort (P¼ 0.021, Figure 2C). This appeared to be
inconsistent with our observations that leptin expression is
associated with chemoresistance. To address this issue, we
investigated the interaction between leptin expression, survival and
whether or not patients had received neoadjuvant chemotherapy.
This analysis revealed that patients with tumours with strong leptin
expression have better survival, but in this group there appears to be
no impact of neoadjuvant chemotherapy on survival. In contrast, for
patients with leptin moderate/weak/negative tumours, survival is
improved in those patients who received neoadjuvant chemotherapy
(Figure 2D, P for interaction¼ 0.038). In multivariate analysis in the
entire cohort (n¼ 154), leptin is significantly associated with
survival (Table 5). Overall, this suggests that leptin expression is
associated with chemoresistance, consistent with the observed
associations in our gene expression profiling experiments, but also
that leptin expression in gastro-oesophageal adenocarcinomas has a
therapy-independent prognostic impact as well.
Leptin staining in stromal cells was observed in 50% of tumours.
There was no significant correlation between leptin staining in the
stroma and leptin tumour cell staining, nor with histopathological
response or survival.
Leptin expression in gastric adenocarcinoma cell lines correlates
with chemoresistance. To extend our findings from patient
samples to an in vitro system, and examine the effects of leptin
on chemosensitivity to individual cytotoxic drugs, we examined the
expression of leptin by IHC in a panel of gastric cancer cell lines
(n¼ 22). Similar to the scoring performed in primary cancers,
leptin expression was categorised as negative, weak, moderate or
strong based upon the intensity of cytoplasmic staining, with
negative¼ 0 out of 22, weak¼ 5 out of 22, moderate¼ 11 out of 22
and strong¼ 6 out of 22 cell lines. Strong leptin protein expression
was significantly associated with lower in vitro sensitivity to
cisplatin in these cell lines (mean GI50 concentration 86.8 mMl 1
vs 16.8 mMl 1, P¼ 0.008, Figure 3). There was no significant
relationship between leptin expression and in vitro sensitivity to
oxaliplatin (P¼ 0.988) or 5FU (P¼ 0.636) (Figure 3). These results
support the potential role of leptin expression in resistance to
cytotoxic chemotherapy and suggest that the impact of leptin
expression may be agent specific.
Leptin receptor antagonist SHLA increases sensitivity to
cisplatin. In order to provide mechanistic evidence for the role
of leptin in response to cisplatin in gastroesophageal adenocarci-
noma, and to investigate the importance of autocrine/paracrine
leptin signalling in cisplatin response, we examined the effect of the
leptin receptor antagonist SHLA (Shpilman et al, 2011) on in vitro
sensitivity to cisplatin. Experiments were performed using two cell
lines that were not part of the previous panel: an oesophageal
adenocarcinoma cell line OE33 and a gastric cancer cell line AGS
Cis5 that had been selected for acquired resistance to cisplatin
(Supplementary Information 5). In both OE33 and AGS Cis5,
SHLA increased sensitivity to cisplatin (Figure 3). In addition,
SHLA inhibited the growth of OE33 cells when given alone, but
not AGSCis5 (Figure 3). In both AGS Cis5 and OE33, SHLA
inhibited leptin-induced cell proliferation (Supplementary
Information 7).
DISCUSSION
We performed gene expression profiling to identify potential
predictive biomarkers of chemotherapy response in patients with
gastro-oesophageal adenocarcinoma. Higher leptin mRNA expression
was associated with lack of radiological response. Subsequently, we
demonstrated that higher leptin protein expression was associated
with lack of histological response to neoadjuvant chemotherapy in
an independent cohort of patients, and with resistance to cisplatin
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Figure 1. Mean leptin mRNA from Affymetrix Exon 1.0 ST Array in
discovery set (n¼14) in radiological responders and nonresponders
(Student’s t-test, P¼ 0.011). Error bars±s.e.m. There is no significant
correlation between tumour leptin mRNA expression and the tumour
cell content of biopsies (P¼0.779).
Table 4. Details of genes from the adipocytokine signalling pathway identified in pathway analysis
Probe set ID
Gene
symbol Gene title
Chromosomal
location
Direction of change, radiological
non-responders vs responders P-value
3022709 LEP Leptin 7q32.1 Up 0.011
2599580 PRKAG3 Protein kinase, AMP-activated, g3 non-catalytic subunit 2q35 Up 0.016
3430959 ACACB Acetyl-Coenzyme A carboxylase-b 12q24.11 Down 0.011
2544625 POMC Pro-opiomelanocortin 2p23.3 Up 0.005
3275922 PRKCQ Protein kinase C, y 10p15.1 Up 0.016
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in a panel of gastric adenocarcinoma cell lines. Patients with lower
leptin tumour expression had better survival when treated with
neoadjuvant chemotherapy, whereas those with higher leptin
expression did not have a survival benefit from neoadjuvant
chemotherapy. Finally, we demonstrated that a leptin receptor
antagonist increased sensitivity to cisplatin, including in a highly
cisplatin-resistant cell line. The strong association of leptin mRNA
and protein expression with both radiological and histopatho-
logical response, and also patient survival and in vitro cisplatin
sensitivity, together with increased cisplatin sensitivity by a leptin
receptor antagonist, provides consistent evidence of the impor-
tance of leptin in gastro-oesophageal cancer pathogenesis and
response to chemotherapy.
Leptin is an adipocytokine that is secreted from adipocytes as
well as other cells, and it acts through specific receptors to control
satiety in the central nervous system, and in peripheral tissues to
regulate glucose and insulin homeostasis and other functions such
as angiogenesis (Bjorbaek and Kahn, 2004). The increased risk of
cancer in obese individuals and the deregulation of adipocytokines
in obesity has led to investigation of leptin signalling in cancer
pathogenesis (VanSaun, 2013). Leptin secretion has been demon-
strated from breast cancer and glioblastoma cells, and autocrine or
paracrine actions appear to be important in carcinogenesis
(Miyoshi et al, 2006; Ferla et al, 2011; Nejati-Koshki et al, 2012).
Epidemiological studies demonstrate a strong relationship between
BMI, visceral adipose tissue and risk of oesophageal and gastro-
oesophageal junction adenocarcinoma (Abnet et al, 2008).
In addition, there are several lines of evidence supporting a role for
leptin in the pathogenesis of gastro-oesophageal adenocarcinoma,
including clinical and preclinical data implicating leptin as a
growth-promoting signal, stimulating proliferation and inhibiting
cell death of gastric and oesophageal adenocarcinoma cells (Pai
et al, 2005; Shida et al, 2005; Ogunwobi et al, 2006; Beales and
Ogunwobi, 2007; Abnet et al, 2008; Howard et al, 2010; Dong et al,
2013). Leptin receptors have been shown to be expressed in the
majority of gastroesophageal adenocarcinomas (Howard et al,
2010). Accordingly, based on our results we hypothesise that leptin
acts via an autocrine or paracrine mechanism involving its specific
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Figure 2. Leptin IHC in gastro-oesophageal adenocarcinomas. (A) Representative IHC (weak and medium  200; strong 400). (B) Leptin IHC
and histopathological response to neoadjuvant platinum-based combination chemotherapy (w2, P¼0.007). Mandard TRG 4–5 have a medium
survival of 23.8 months and Mandard TRG 1–3 median survival not reached but472 months (Kaplan–Meier analysis, log rank P¼0.009, data not
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receptor(s) in gastro-oesophageal adenocarcinoma tumour cells,
promoting cell survival and hence chemoresistance in the presence
of a cytotoxic drug insult.
We observed no significant correlation between BMI and leptin
tumour expression (R¼ 0.006, P¼ 0.983) or between BMI and
response to chemotherapy (nonresponders¼ 31.4 vs responders¼
28.5, P¼ 0.293). Our study was not adequately powered or intended
to address the question of whether tumour leptin concentration
correlates with BMI. A larger study would be required to fully
investigate any relationship between tumour leptin and BMI. In light
of our findings implicating tumour leptin expression in resistance to
therapy, an investigation of the relationship between tumour leptin
expression, serum leptin concentration, BMI, visceral adiposity and
therapy outcome would be valuable to provide new insights into
gastro-oesophageal cancer pathogenesis.
Interestingly, higher leptin protein expression was also asso-
ciated with improved survival in the absence of neoadjuvant
chemotherapy, implying contrasting predictive and therapy-
independent prognostic impacts. Similar associations between
leptin expression and improved therapy independent prognosis
have been reported in colorectal and breast cancer (Kim, 2009;
Paik et al, 2009). Similar contrasting relationships between
response to treatment and prognosis have been observed for other
markers, most notably for oestrogen receptors (ER) in breast
cancer, where ER expression correlates with not only chemoresis-
tance but also better survival, and is also a useful therapeutic target
(Petit et al, 2010). In addition, recently in triple-negative breast
cancer, high BCL2 expression by IHC was noted to be associated
with a lack of benefit from adjuvant anthracycline-based
chemotherapy but a better therapy-independent prognosis
(Abdel-Fatah et al, 2013). This is similar to our findings in
gastro-oesophageal cancer of high leptin leading to specific
chemotherapy resistance but better overall prognosis. These
findings suggest that clinically relevant molecular mechanisms
exist that lead to resistance to chemotherapy but a better therapy-
independent prognosis (and the converse of worse therapy-
independent prognosis that is improved by sensitivity to
chemotherapy). We believe characterisation of such mechanisms
is important as they allow the discovery of clinically very useful
biomarkers that identify chemotherapy regimens that will be
ineffective, but whose occurrence are associated with a better
prognosis subset of patients in whom other targets might be more
optimally pursued.
The predictive and prognostic impact of leptin tumour
expression demonstrated in the current study suggests that it has
potential utility as a biomarker. High tumour leptin expression
would identify a tumour that is chemoresistant, but has a good
therapy-independent prognosis, whereas low tumour leptin
expression would identify a tumour with a poor therapy-
independent prognosis that is chemosensitive, implying that
chemotherapy is likely to improve outcome in patients with low
tumour leptin expression. In the 64 patients who received
neoadjuvant chemotherapy before surgery, 0 out of 32 patients
in the strong leptin expression group had major histopathological
responses (Mandard TRG 1 or 2). All major histological responses
occurred in the negative/weak/moderate leptin expression group.
Therefore, although tumours with strong leptin protein expression
are unlikely to respond to and hence benefit from neoadjuvant
chemotherapy, some clinicians might believe that even a low
probability of a minor response (12% chance of moderate –
Mandard TRG3 – response in leptin high protein expression in our
series) would justify the administration of neoadjuvant chemotherapy.
However, strong leptin-positive patients have a good therapy-
independent prognosis – the estimated 5-year survival in our series
is 50% in strong leptin expression patients who did not have
neoadjuvant chemotherapy – that is not significantly different
from leptin-positive patients who were given neoadjuvant
chemotherapy (estimated 5-year survival 52%).
To confirm the predictive and prognostic impact of tumour
leptin expression, a prospective investigation of leptin expression
in tumours from a randomised study would need to be undertaken.
This could be performed as a ‘prospective-retrospective’ analysis
using available tissue collections from neoadjuvant chemotherapy
trials where randomisation to chemotherapy and surgery or
surgery alone was undertaken. The development and technical
validation of an IHC assay for leptin in our study means that this is
feasible and the magnitude of the effect of leptin that we have
observed suggests that tissue collections available from such trials
would be adequately powered. Ultimately, further technical
validation and optimisation would be required to produce a robust
leptin IHC assay for routine clinical application. Our gene
expression profiling discovery set also included patients with
advanced disease who received palliative chemotherapy and hence
leptin may also be useful as a predictive biomarker for palliative
chemotherapy in advanced disease. This role of leptin would also
require prospective qualification. In a prospective qualification
study, it would also be important to determine whether the effect of
leptin on chemosensitivity is specific to certain chemotherapy
drugs, as is perhaps suggested by the data from our gastric cancer
cell line panel, or a more general effect.
In the discovery set, all 4 nonresponders and 6 out of 10
responders received ECX (Table 1). In light of our cell line
findings, the inclusion of patients not treated with cisplatin, but
instead with oxaliplatin, may have affected the results from the
original discovery cohort. However, if, as the cell line studies
suggest, leptin is associated with resistance to cisplatin and not
oxaliplatin, treatment with oxaliplatin and not cisplatin in the
responding group would have potentially diluted any relationship
between leptin and resistance. Therefore, we do not believe that the
inclusion of patients not treated with cisplatin has critically
influenced the study outcome; in addition, the impact of leptin on
chemosensitivity and clinical outcome for neoadjuvant ECX
chemotherapy has been validated. In the absence of any qualified
biomarkers for chemotherapy response in gastro-oesophageal
adenocarcinoma, a discovery approach using gene expression
profiling to identify leads for novel predictive biomarkers is
justified, and the analysis of tumour specimens from patients
treated with chemotherapy represents the most clinically relevant
translational experimental model. However, adopting this
approach means that patients receive combination regimens as
Table 5. Multivariate analysis using Cox proportional hazards model in
the independent tissue microarray series (n¼ 154)
Variable HR (95% CI) P-value
Resection margin
Positive (R1) vs negative (R0) 1.23 (1.05–1.44) 0.012
Leptin immunohistochemistry positive
Strong vs moderate/weak/negative 0.85 (0.73–0.99) 0.040
Stage
III/IV vs I/II 1.78 (1.37–2.28) 0.001
Neoadjuvant chemotherapy
Yes vs no 0.64 (0.38–1.03) 0.062
Tumour site
Gastric vs oesophageal 0.70 (0.43–1.16) 0.165
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio.
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this is standard clinical practice, and necessitates further
investigation to determine the effects of any leads on individual
drugs (as we have undertaken for leptin), because for clinical
application it is important to determine the effect of markers on
individual drugs. However, the approach also has the significant
advantage of capturing data from clinical response involving the
majority of the drugs commonly used in the advanced and
neoadjuvant settings for gastro-oesophageal adenocarcinomas, and
hence provides the opportunity to identify molecules that may be
involved in response or resistance to multiple agents that are hence
potentially of great value as predictive biomarkers or targets.
Overall, our experimental approach in the discovery set provided
the greatest opportunity to identify leads from gene expression
profiling that would have clinical and translational relevance,
but required that leads would need to be validated in specific
cohorts of patients and in vitro model systems – as we have
undertaken.
The discordant effects of leptin on resistance to cisplatin and
oxaliplatin observed in our gastric cancer cell line panel are
interesting and of potential value for the use of leptin as a
predictive biomarker. A randomised trial has demonstrated that
oxaliplatin is equivalent to cisplatin in the treatment of advanced
gastro-oesophageal adenocarcinoma (Cunningham et al, 2008).
However, although related, there are also differences in the
mechanisms of action of cisplatin and oxaliplatin, and preclinical
investigation in gastric cancer suggests that there are distinct
subsets that exhibit differential sensitivity to oxaliplatin and
cisplatin. Gene expression profiling of gastric cancer cell lines
(validated in primary gastric cancer tumour specimens) identified
two subsets with differential sensitivity to oxaliplatin and cisplatin
(Tan et al, 2011). In addition, molecular determinants of resistance
to cisplatin have been demonstrated in gastric cancer that do not
affect oxaliplatin sensitivity (Ivanova et al, 2013). In our gastric
adenocarcinoma cell line panel, there is no correlation between
IC50 for cisplatin and oxaliplatin (R¼  0.078, P¼ 0.730) or
between IC50 for cisplatin and 5FU (R¼ 0.084, P¼ 0.780), but
oxaliplatin and 5FU GI50 do significantly correlate (R¼ 0.0494,
P¼ 0.019 and Supplementary Information 6). These consistent
observations suggest that differential sensitivity to oxaliplatin and
cisplatin occurs in gastro-oesophageal cancer and implies the
existence of distinct mechanisms of action and determinants of
resistance and sensitivity to these two cytotoxic drugs. Our data
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suggest that leptin may play a similar role in mediating
differential sensitivity to oxaliplatin and cisplatin in gastro-
oesophageal adenocarcinomas. A differential effect on sensitivity
to oxaliplatin and cisplatin would enhance the clinical utility
of leptin as a clinical predictive biomarker as high leptin would
imply resistance to cisplatin, but sensitivity maintained to
oxaliplatin that would be a suitable alternative agent to use in
such patients.
There have been conflicting results for the impact of the tumour
expression of leptin on prognosis in human cancer, including
gastric cancer. Methodological issues and patient case mix in series
are more likely to provide explanations for these differences rather
than tumour biology. Specifically, Geng et al (2012) reported leptin
IHC associated with worse survival in 110 patients with resected
gastric cancer; however although it is apparent that some patients
have received chemotherapy, it is not reported what the
chemotherapy regimen is or whether the chemotherapy was given
adjuvant, neoadjuvant or on relapse. Leptin IHC expression in
tumours is reported as being an independent factor in the Cox
regression survival analysis that also includes ‘absence’ of
chemotherapy, but the specific impact of leptin in chemother-
apy-treated patients is not reported. In light of our data reporting a
significant interaction between leptin tumour expression and
chemotherapy response, it is difficult to interpret the clinical
relevance of Geng et al data and to make valid comparisons with
our own data set in which the interaction of leptin and
chemotherapy has been examined. The choice of threshold
between leptin IHC positive and negative has the potential to
strongly influence outcome data in retrospective studies. In our
series, the biological rationale for the threshold we used can be
demonstrated by examination of the KM curves in Figure 2C that
shows a ‘dose response’ relationship between leptin expression and
survival – in this figure, the distinct survival outcome of leptin
strong positive cases can be seen, whereas moderate or weak
staining show no distinct difference from each other. In the paper
by Geng et al, no data regarding the dose–response relationship
between leptin IHC and outcome are presented and, accordingly,
no rationale for the applied cutoff threshold they have used in their
analysis. Zhao et al (2007) demonstrated no relationship between
leptin IHC and survival after surgery for gastric cancer patients
with KM survival analysis, and it is therefore surprising that leptin
is subsequently reported as an independent prognostic factor in the
Cox multivariate analysis. This inconsistency suggests that caution
should be applied in the interpretation of these data that may
reflect the balance of chance alone.
The interaction between leptin expression and response to
chemotherapy and the therapy-independent prognostic impact
demonstrated in our data suggests that leptin may be a useful
therapeutic target in gastro-oesophageal adenocarcinoma.
A number of leptin receptor antagonists have been developed for
therapeutic use, including as anticancer agents, with several
completing preclinical testing and they are likely to enter early-
phase clinical trials soon (Otvos et al, 2011; Shpilman et al, 2011;
Gertler and Solomon, 2013). We chose to examine the effect of a
leptin receptor antagonist on cisplatin sensitivity in gastro-
oesophageal adenocarcinoma in order to further evaluate the role
of leptin signalling, particularly autocrine and paracrine signalling
and, given the stage of development of leptin receptor antagonists,
to evaluate the translational potential of such agents as novel
therapeutics. Our data suggest that leptin receptor antagonists may
be useful to administer in combination with chemotherapy, or as
monotherapy – administration with chemotherapy may reverse
clinical resistance and increase response rates; alternatively,
high tumour leptin expression may indicate a chemoresistant
tumour that is dependent upon leptin signalling and that may
be more optimally treated by a leptin antagonist, avoiding
chemotherapy.
In conclusion, the results presented indicate that leptin could be
a useful clinical biomarker in gastro-oesophageal adenocarcinoma
for chemotherapy selection and also a novel therapeutic target. We
believe that further prospective biomarker qualification studies and
mechanistic investigations are indicated.
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